Anavex Life Sciences - AVXL STOCK NEWS

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference. Christopher U. Missling, PhD, President and CEO, will present on February 25th, 2021, at 12:00 p.m. EST, discussing the company's progress on therapeutics for neurodegenerative disorders like Alzheimer’s and Parkinson’s. The presentation will be available via webcast and can be replayed online. Anavex is known for its lead drug candidate, ANAVEX®2-73, which recently completed successful clinical trials.

Anavex Life Sciences Corp. (Nasdaq: AVXL) reported its financial results for the fiscal quarter ended December 31, 2020, posting a net loss of $7.9 million, or $0.12 per share. As of the reporting date, the company had approximately $75 million in cash and cash equivalents, providing a runway for up to three years. ANAVEX®2-73 is advancing in clinical trials for Alzheimer’s, Parkinson’s, and Rett syndrome, with 86% recruitment in the ongoing Phase 2b/3 Alzheimer's trial. Recent milestones include a $995,862 research grant from the Michael J. Fox Foundation.

Anavex Life Sciences Corp. (Nasdaq: AVXL) will release its financial results for the fiscal quarter ending December 31, 2020, on February 11, 2021. A conference call will be held at 4:30 pm ET to discuss these results, along with updates on clinical programs and corporate highlights. Anavex is focused on developing therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. The company’s lead candidate, ANAVEX®2-73, has shown promise in clinical trials targeting significant CNS diseases.

Anavex Life Sciences Corp. (Nasdaq: AVXL) has received a research grant of $995,862.51 from The Michael J. Fox Foundation for Parkinson’s Research to further develop ANAVEX®2-73 (blarcamesine) as a treatment for Parkinson’s disease. This funding follows a previous award that supported preclinical studies indicating the drug’s potential as a disease-modifying treatment. ANAVEX®2-73 targets the sigma-1 receptor, crucial for promoting neuroplasticity and restoring neural cell homeostasis. Parkinson's disease affects over 10 million people globally, underlining the significance of this research.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced that Christopher U. Missling, PhD, will present at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. This clinical-stage biopharmaceutical company focuses on developing innovative therapies for neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases. Anavex's lead drug candidate, ANAVEX®2-73, has shown promise in recent clinical trials, demonstrating its ability to restore cellular balance and potentially reverse Alzheimer’s disease progression. A webcast of the presentation will be available on Anavex’s website.

Anavex Life Sciences Corp. (AVXL) announced its fiscal year 2020 results, reporting a net loss of $26.3 million, or $0.45 per share, consistent with the previous year. The company has cash reserves of $47.6 million. Key advancements include successful trials for ANAVEX®2-73 in Rett syndrome and Parkinson's disease dementia, with future pivotal trials planned. The firm aims to engage the FDA regarding accelerated approval. Anavex’s patent application for ANAVEX®2-73 has been allowed, extending protection until at least 2037.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced a conference call on December 28, 2020, at 4:30 PM ET to discuss financial results for its fiscal year ending September 30, 2020. The company focuses on therapeutics for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Anavex's lead candidate, ANAVEX®2-73, has shown promise in various clinical trials, including a successful Phase 2a trial for Alzheimer’s disease. The call will include a Q&A session with equity analysts, allowing for insights on clinical programs and corporate developments.

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced a webinar hosted by Ladenburg Thalmann on December 22, 2020, at 3:30 p.m. ET. The webinar will focus on Rett Syndrome and Phase 2 data for ANAVEX®2-73 (blarcamesine). Esteemed speakers include Dr. Jeffrey Neul and Dr. Randi Jenssen Hagerman, with Robert LeBoyer moderating. ANAVEX®2-73 has shown promising results in Phase 2 clinical trials for Alzheimer’s disease and Parkinson’s disease dementia. The webinar aims to discuss its potential in treating neurodevelopmental disorders.

On December 15, 2020, Anavex Life Sciences Corp. (Nasdaq: AVXL) announced positive results from a Phase 2 trial of ANAVEX®2-73 (blarcamesine) for treating Rett syndrome in adult females. The trial met primary safety and secondary efficacy endpoints, showing statistically significant improvements in Rett syndrome symptoms, particularly in the Rett Syndrome Behaviour Questionnaire (RSBQ) and Clinical Global Impression Improvement Scale (CGI-I). All participants exhibited a favorable safety profile, leading to plans for an FDA meeting regarding the approval pathway for ANAVEX®2-73.